Department of Urology, HEGP, Paris, France; Université Paris Descartes, Faculté de Médecine, Paris, France.
Université Paris Descartes, Faculté de Médecine, Paris, France; Department of Adult Radiology, Hôpital NECKER - Enfant Malades, Paris, France.
Clin Genitourin Cancer. 2020 Apr;18(2):138-147. doi: 10.1016/j.clgc.2019.10.006. Epub 2019 Oct 16.
The purpose of this study was to assess oncologic and functional outcomes of both percutaneous ablation (cryoablation and radiofrequency ablation) and robot-assisted partial nephrectomy (RAPN) in the treatment of renal tumors larger than 4 cm.
We retrospectively analyzed prospectively collected data from 102 consecutive patients, who underwent minimally invasive treatment for cT1b renal tumors at our institution. Primary renal function outcome was assessed by estimated glomerular filtration rate preservation at baseline and 1 year postoperatively. Perioperative data and functional and oncologic outcome were collected. Multivariate regression models were used to compare functional outcomes between groups. Cancer-specific survival and recurrence-free survival were estimated at 2 years using the Kaplan-Meier method and compared with Cox proportional hazards regression model to calculate hazard ratios (HRs). To control for selection bias between the different treatments, we adjusted our models with an inverse probability of treatment weighting propensity score.
There was no significant difference in renal preservation between the groups (P = .664). Multivariate analysis did not show a statistically significant difference in terms of renal function outcomes between the RAPN and percutaneous thermal ablation groups. The adjusted HR regarding the local recurrence-free survival was significantly shorter for the cryoablation group (HR, 4.3; 95% confidence interval, 1.78-10.37; P = .001).
Our study demonstrated the equivalence between RAPN and percutaneous ablative techniques for the preservation of renal function in the treatment of T1b tumors. RAPN offers a better local control than percutaneous ablation, in terms of primary success rate.
本研究旨在评估经皮消融(冷冻消融和射频消融)和机器人辅助部分肾切除术(RAPN)治疗大于 4cm 的肾肿瘤的肿瘤学和功能结果。
我们回顾性分析了在我院接受微创治疗 cT1b 肾肿瘤的 102 例连续患者的前瞻性收集数据。通过基线和术后 1 年的估算肾小球滤过率保留来评估原发性肾功能结果。收集围手术期数据以及功能和肿瘤学结果。使用多变量回归模型比较两组之间的功能结果。使用 Kaplan-Meier 方法在 2 年内估计癌症特异性生存率和无复发生存率,并使用 Cox 比例风险回归模型计算风险比(HRs)。为了控制不同治疗方法之间的选择偏倚,我们使用逆概率治疗加权倾向评分调整了我们的模型。
两组之间的肾脏保留没有显著差异(P=0.664)。多变量分析显示,RAPN 和经皮热消融组在肾功能结果方面没有统计学上的显著差异。冷冻消融组局部无复发生存的调整 HR 明显较短(HR,4.3;95%置信区间,1.78-10.37;P=0.001)。
我们的研究表明,RAPN 和经皮消融技术在治疗 T1b 肿瘤时在保留肾功能方面具有等效性。在原发性成功率方面,RAPN 提供了比经皮消融更好的局部控制。